Here's why Biogen's promising Alzheimer's drug data is also good news for Eli Lilly

We don't own Eli Lilly exclusively for its potential Alzheimer's treatment. However, we still find Biogen's topline data to be very encouraging for Lilly.

Here's why Biogen's promising Alzheimer's drug data is also good news for Eli Lilly

The Eli Lilly logo is shown on one of the company's offices in San Diego, California, September 17, 2020.

Mike Blake | Reuters